Huntley Geoffrey D, Deshmukh Abhishek J, Warnes Carole A, Kapa Suraj, Egbe Alexander C
School of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Pediatr Cardiol. 2018 Oct;39(7):1476-1483. doi: 10.1007/s00246-018-1919-3. Epub 2018 Jun 14.
Placement of an epicardial pacemaker system is often preferred over an endocardial system in patients who have undergone a Fontan operation, but data are limited on how these two systems perform over time in patients with Fontan palliation. We performed a retrospective review of adults with Fontan palliation who had pacemaker implantation and interrogation data at Mayo Clinic from 1994 to 2014. Lead parameters, pacing mode, and polarity were collected at the earliest device interrogation report. Clinic notes and device interrogation reports were reviewed at implantation, 6 months, and yearly after implantation to determine impedance, capture threshold (CT), and energy threshold (ET). There were 87 patients with 168 leads in the study cohort. The mean follow-up time was 7.7 years (6 months-19 years). There were 143 epicardial leads (57 atrial and 86 ventricular) and 25 endocardial leads (20 atrial and 5 ventricular). There was no difference in the baseline lead parameters between epicardial and endocardial leads for impedance (610 ± 259 versus 583 ± 156 Ω, p = 0.93), CT (2.0 ± 1.3 versus 1.8 ± 1.3 V, p = 0.28), or ET (7.1 ± 12.5 versus 6.8 ± 18.1 µJ, p = 0.29). Compared to endocardial leads, ventricular epicardial leads were associated with temporal decrease in impedance and increase in ET. Regarding clinical outcomes, epicardial leads had higher rates of failure but similar generator longevity in comparison to endocardial leads. Ventricular epicardial leads were associated with temporal decrease in impedance and increase in ET. Epicardial leads had a higher rate of failure but similar generator longevity compared to endocardial leads.
对于接受过Fontan手术的患者,心外膜起搏器系统的植入通常比心内膜系统更受青睐,但关于这两种系统在Fontan姑息治疗患者中的长期表现的数据有限。我们对1994年至2014年在梅奥诊所植入起搏器并拥有问询数据的Fontan姑息治疗成年患者进行了一项回顾性研究。在最早的设备问询报告中收集导联参数、起搏模式和极性。在植入时、植入后6个月以及每年对临床记录和设备问询报告进行复查,以确定阻抗、捕捉阈值(CT)和能量阈值(ET)。研究队列中有87例患者,共168根导联。平均随访时间为7.7年(6个月至19年)。有143根心外膜导联(57根心房导联和86根心室导联)和25根心内膜导联(20根心房导联和5根心室导联)。心外膜导联和心内膜导联在基线导联参数方面,阻抗(610±259对583±156Ω,p = 0.93)、CT(2.0±1.3对1.8±1.3V,p = 0.28)或ET(7.1±12.5对6.8±18.1µJ,p = 0.29)均无差异。与心内膜导联相比,心室心外膜导联与阻抗随时间下降和ET升高有关。关于临床结果,心外膜导联的故障率较高,但与心内膜导联相比,发生器寿命相似。心室心外膜导联与阻抗随时间下降和ET升高有关。与心内膜导联相比,心外膜导联的故障率较高,但发生器寿命相似。